GCDH

Glutaryl-CoA dehydrogenase, mitochondrial · Q92947 · GCDH on Sugi Atlas →

603 patent compounds predicted against GCDH, 396 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Balsalazide (SCHEMBL118300)	1.00	3/20
Balsalazide (SCHEMBL138311)	1.00	3/20
Balsalazide (SCHEMBL3267109)	1.00	3/20
Balsalazide (SCHEMBL29377041)	1.00	3/20
Balsalazide (SCHEMBL134019)	0.97	3/20
Balsalazide (SCHEMBL5598491)	0.97	3/20
Balsalazide (SCHEMBL7908058)	0.97	3/20
Balsalazide (SCHEMBL28818120)	0.97	3/20
Balsalazide (SCHEMBL133200)	0.95	3/20
Balsalazide (SCHEMBL17392780)	0.87	3/20
Balsalazide (SCHEMBL20184744)	0.87	3/20
SCHEMBL2628412	0.80	3/20
SCHEMBL11160268	0.79	3/20
SCHEMBL14453551	0.76	3/20
SCHEMBL26843447	0.73	3/20
SCHEMBL2516217	0.71	3/20
SCHEMBL26850099	0.70	3/20
Balsalazide (SCHEMBL3667344)	0.68	3/20
Balsalazide (SCHEMBL30360)	0.67	3/20
SCHEMBL16778320	0.67	3/20

Clinical trials — most relevant to GCDH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:	PHASE3	ACTIVE_NOT_RECRUITING
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis	PHASE2	UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)	PHASE2	RECRUITING
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults	nan	COMPLETED
GDF-15 as a Biomarker for Mitochondrial Disease	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Study of Protein Translocation in Patients With Beta-Oxidation Disorders	nan	COMPLETED
Evaluation of Hydroxymethylbutyrate Supplementation in Lung Transplant Candidates Receiving Pulmonary Rehabilitation	nan	COMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
McArdle Disease Treatment by Ketogenic Diet	nan	COMPLETED
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy	nan	UNKNOWN
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency	nan	NO_LONGER_AVAILABLE
Mitochondrial Assessment in Critical Ill Patients in Intensive Care	nan	NOT_YET_RECRUITING
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)	nan	RECRUITING
11C-Acetate PET/CT Non-FDG-Avid Tumors	nan	UNKNOWN
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders	nan	COMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)	nan	UNKNOWN
Longitudinal Study of Mitochondrial Hepatopathies	nan	SUSPENDED
KETO-TUMOR: a Study on Brain Tumors and Central Obesity	nan	RECRUITING
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GCDH binder may also engage these)

Protein	Name	Similarity
Q2KHZ9	—	0.998	Q2KHZ9 →
Q8HXX8	—	0.997	Q8HXX8 →
Q60759	—	0.993	Q60759 →
P81140	—	0.975	P81140 →
Q20772	—	0.965	Q20772 →
Q54R47	—	0.946	Q54R47 →
P61922	—	0.933	P61922 →
P50554	—	0.932	P50554 →
Q9BGI0	—	0.930	Q9BGI0 →
Q64380	—	0.928	Q64380 →
ABAT	4-aminobutyrate aminotransferase, mitochondrial	0.927	landscape →
CTH	Cystathionine gamma-lyase	0.925	landscape →
OAT	Ornithine aminotransferase, mitochondrial	0.924	landscape →
Q91WC3	—	0.923	Q91WC3 →
Q99LB7	—	0.923	Q99LB7 →
P04182	—	0.923	P04182 →
Q5RDE7	—	0.922	Q5RDE7 →
P29758	—	0.922	P29758 →
Q9NUZ1	—	0.921	Q9NUZ1 →
P80147	—	0.921	P80147 →
Q60HG7	—	0.920	Q60HG7 →
P40142	—	0.920	P40142 →
Q5I0K3	—	0.920	Q5I0K3 →
Q8R4N0	—	0.919	Q8R4N0 →
Q6B855	—	0.919	Q6B855 →
Q9Z1J3	—	0.919	Q9Z1J3 →
Q96329	—	0.918	Q96329 →
Q3ZCF5	—	0.917	Q3ZCF5 →
Q9UL12	—	0.917	Q9UL12 →
ACADVL	Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	0.917	landscape →